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A B S T R A C T
Background: Late gadolinium enhancement (LGE) is a standard method to evaluate myocardial ﬁbrosis,
but restricted due to contrast agent contraindications. Non-contrast T1rho can generate endogenous
contrast, and detect ﬁbrosis in chronic myocardial infarction. However, T1rho for hypertrophic
cardiomyopathy (HCM) patients is still unreported. The present study aimed to investigate T1rho for
ﬁbrotic assessment and the clinical implication in HCM patients.
Methods: 18 HCM patients and 8 controls underwent T1rho, cine, and LGE cardiac magnetic resonance
(CMR). T1rho relaxation time maps were created. Left ventricular (LV) parameters assessed included
wall thickness, wall thickening, chamber volumes, ejection function, and ﬁbrotic size. New York Heart
Association (NYHA) functional classiﬁcation was conducted.
Results: Hyper-T1rho value was identiﬁed in 12 HCM patients, consistent with LGE. The mean T1rho
values of controls, LGE-negative patients, and remote myocardium of LGE-positive patients were
42.2  1.6 ms, 43.9  2.5 ms, and 42.5  1.2 ms respectively, and these values showed no signiﬁcant
difference (all p > 0.05). T1rho-3-SD and T1rho-4-SD ﬁbrotic sizes (32.5  14.0% and 25.1  11.5%) did not
differ from LGE ﬁbrotic size (28.1  11.2%) (both p > 0.05). For the ﬁbrotic size, T1rho-3-SD method obtained
the strongest correlation with LGE (r = 0.88, p < 0.001), and T1rho-4-SD obtained the minimal mean
difference with LGE (3.1%; 15.2 to 9.1%), compared with other SDs. All the ﬁbrotic sizes assessed by both
methods correlated directly with LV maximal end-diastolic thickness (all p < 0.05). Negative correlation was
found between T1rho-4-SD ﬁbrotic size and LV ejection fraction (r = 0.49, p = 0.11). T1rho-4-SD ﬁbrotic size
showed positive correlation with NYHA class (r = 0.46, p = 0.13).
Conclusions: T1rho CMR has potential to detect ﬁbrosis in HCM patients. 4-SD may be the appropriate
threshold for assessment.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Hypertrophic cardiomyopathy (HCM) is a primary myocardial
disease with highly heterogeneous clinical presentations ranging
from asymptomatic to severe symptomatic expressions. HCM
patients suffer from diastolic and systolic dysfunctions [1–4]
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0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsmyocardial ﬁbrosis, and small vessel disease [5–7]. HCM is a
leading cause of sudden cardiac death in young individuals,
including athletes [8,9]. Thus, efﬁcient techniques for diagnosis
and risk stratiﬁcation for HCM are indeed needed. Cardiac
magnetic resonance (CMR) provides morphological and functional
information with satisfactory temporal and spatial resolution. Late
gadolinium enhancement (LGE) can provide abundant information
about myocardial ﬁbrosis in HCM patients [10], which is
considered to have signiﬁcant value in cardiac remodeling and
prognosis. Moreover, LGE volume or extent is associated with left
ventricular (LV) systolic function and impaired New York Heart
Association (NYHA) functional class [11,12]. reserved.
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the challenge remains in patients with contrast agent contra-
indications. T1rho CMR with endogenous contrast may overcome
the limitations of contrast-enhanced approaches [13]. This emerg-
ing and innovative technique has been used to study articular
cartilage [14], intervertebral disc [15], brain [16], and liver [17], but
less in heart [18]. Hyper-intensity in the myocardial T1rho map
was observed in LGE areas of swine chronic myocardial infarction
(MI) model [13]. However, to our best knowledge, T1rho imaging
for HCM patients is still unreported. In the present study, we made
an effort to evaluate whether T1rho CMR is able to assess ﬁbrosis,




This prospective study included 18 patients diagnosed with
HCM between December 2012 and April 2014. The deﬁnition of
HCM was based on the World Health Organization/International
Society and Federation of Cardiology criteria [19]. NYHA classiﬁ-
cation was evaluated independently by two experienced cardiol-
ogists. In addition, eight subjects without cardiovascular disease
history were recruited as healthy controls. The study protocol was
approved by the local human study committee after obtaining
written informed consent from each participant.
CMR protocol
CMR was performed on a 3.0 Tesla magnetic resonance imaging
(MRI) system (Magnetom Trio, Siemens Medical Systems, Erlan-
gen, Germany) with a commercially available cardiac surface coil.
The T1rho images were obtained using an electrocardiogram
(ECG)-gated T1rho prepared gradient echo sequence in three
short-axis slices from the base to the apex. This T1rho sequence
was previously reported to be able to reduce B0 and B1 ﬁeld
inhomogeneities [20]. Each slice can obtain three T1rho images
with different time of spin locking (TSL) in a segmented fashion
within a single breath-hold. Imaging parameters were: repetition
time (TR) 3.2 ms, echo time (TE) 1.52 ms, ﬂip angle 158, bandwidth
606 Hz/Px, ﬁeld-of-view (FOV) 172 mm  232 mm, voxel size
1.8 mm  1.8 mm  8.0 mm, locking ﬁeld B1 8uT, TSL 10, 30,
50 ms, and spin locking frequency (SLF) 340.6 Hz. Larger SLF was
restricted by the speciﬁc absorption rate (SAR) limit imposed on
the CMR system.
Cine CMR sequence was then performed in the 4-chamber, 3-
chamber, 2-chamber and short-axis views from the base to theFig. 1. Wall thickening of left ventricular (LV) maximal end-diastolic wall thickness (EDT
thickness (ESTH) of the same site (arrowed line in the right panel) were used to calculate
formula: (ESTH–EDTH)/EDTH  100%. ED, cine image at end-diastole; ES, cine image aapex. Short-axis images of 12–14 sections were obtained using a
steady-state free precession with retrospective ECG triggering.
Image parameters were: TR 3.0 ms, TE 1.5 ms, ﬂip angle 508,
bandwidth 977 Hz/Px, FOV 172 mm  227 mm, and voxel size
1.3 mm  1.3 mm  8.0 mm.
LGE images were obtained 10–15 min after a bolus adminis-
tration of gadolinium-DTPA (0.15 mmol/kg, Magnevist, Bayer
Health Care Pharmaceuticals, Leverkusen, Germany) using an
ECG-gated breath-hold inversion recovery Turbo FLASH in short-
axis and long-axis slices. The infusion rate of contrast agent was
3 ml/min, followed by the saline ﬂush (2–3 ml more than volumes
of Magnevist) with the same injection rate. Imaging parameters
were: TR 6.5 ms, TE 3.55 ms, inversion time 300–360 ms (depend-
ing on patients’ heart rates), ﬂip angle 208, bandwidth 287 Hz/Px,
FOV 172 mm  232 mm, voxel size 1.8 mm  1.4 mm  8.0 mm.
Image analysis
The CMR data were reviewed independently by two experi-
enced cardiac radiologists blind to the clinical parameters. LV
mass, chamber volume, and function were analyzed in the cine
short-axial images with the Argus software (Siemens Medical
Systems, Erlangen, Germany). LV maximal end-diastolic wall
thickness (EDTH) and end-systolic wall thickness (ESTH) of the
same site were manually measured with syngo-fV (Siemens
Medical Systems) (Fig. 1). The wall thickening of LV maximal EDTH
was computed: (ESTH–EDTH)/EDTH x 100%. The T1rho relaxation
time maps were created by a custom-made software written in
Matlab 7.1 (The Mathworks, Natick, MA, USA). The remote area of
HCM patients was deﬁned visually as a region of myocardium
without LGE. The mean relaxation time and SD of controls or
remote area were determined by drawing a region of interest (ROI,
at least 50 pixels) in normal or remote myocardium each slice with
ImageJ (NIMH, NIH, Bethesda, MD, USA). Fibrotic size was traced
manually and quantiﬁed with ImageJ using 3 slices (from the base
to the apex) LGE images or T1rho relaxation time maps before
being multiplied by 1.05 g/cm3 [1] (expressed in gram). LGE for
ﬁbrotic size was performed visually, while T1rho for ﬁbrotic size
using threshold technique with 2 SDs, 3 SDs, 4 SDs, 5 SDs, and 6 SDs
above the mean T1rho value of the remote myocardium. The
percent ﬁbrotic size was expressed as a percentage of the total 3-
slice mass (g): (Mﬁbrotic/Mtotal)  100%, with ﬁbrotic mass (Mﬁbrotic)
and total 3-slice mass (Mtotal).
Statistical analysis
All the data are expressed as mean  SD, unless stated otherwise.
Comparison of continuous variables was conducted with the one-wayH). EDTH of LV maximal wall (arrowed line in the left panel) and end-systolic wall
 the wall thickening. The wall thickening of LV maximal EDTH was computed by the
t end-systole.
Table 1
Characteristics of HCM patients and controls.
HCM (n = 18) Control (n = 8) p
Age (y) 52  14 43  10 0.12
Females 9 [50] 5 [63] 0.56
Dyspnea 2 [11] –
Syncope 6 [33] –
NYHA (I/II/III/IV) 8/4/4/2 –
LV mass (g) 151.2  35.7 89.0  20.7 <0.001
LVEDV (ml) 135.0  42.9 142.9  25.5 0.64
LVESV (ml) 59.4  41.3 52.4  8.4 0.64
LVSV (ml) 75.9  19.4 90.5  18.9 0.09
LVEF (%) 58.3  13.1 63.1  3.5 0.33
LV maximal EDTH
(mm)
23.6  5.1 8.3  1.0 <0.001
Wall thickening of
LV maximal EDTH (%)
24.2  16.8 77.5  23.5 <0.001
Data are presented as mean  SD or n [%]. HCM, hypertrophic cardiomyopathy;
NYHA, New York Heart Association; LV, left ventricular; LVEDV, LV end-diastolic
volume; LVESV, LV end-systolic volume; LVSV, LV stroke volume; LVEF, LV ejection
fraction; EDTH, end-diastolic wall thickness.
C. Wang et al. / Journal of Cardiology 66 (2015) 520–526522ANOVA test. Comparison of proportions was performed by chi-square
analysis. Relationships between variables were determined by
Pearson correlation. All the comparisons and correlations were
two-tailed, and a p < 0.05 was considered to be statistically
signiﬁcant. Above data processing and statistical analyses were
performed using the SPSS V.13.0 statistical program (SPSS Inc.,
Chicago, IL, USA). Limits of agreement for ﬁbrotic sizes between LGE
and T1rho CMR were determined by Bland–Altman analysis using
MedCalc V.11.4.2.0 (MedCalc Software bvba, Ostend, Belgium).Fig. 2. T1rho relaxation time mapping in a late gadolinium enhancement (LGE)-positive p
hyper-T1rho area (red arrow in A2) and LGE area (red arrow in A1), whereas no hyper-T1r
C1). (A1, B1, and C1) LGE images of the patients and control. (A2, B2, and C2) T1rho reResults
Characteristics of patients
A total of 18 HCM patients and 8 controls were included in the
analysis, and the characteristics are presented in Table 1. There
were no signiﬁcant differences in age and gender between patients
and controls (all p > 0.05). Mean age of patients was 52  14 years
(range: 25–71 years), and nine (50%) were females. The average LV
mass of patients was 151.2  35.7 g (range: 91.4–220.2 g), and
obviously greater than that of controls (89.0  20.7 g, p < 0.001). LV
maximal EDTH in patients (23.6  5.1 mm) was signiﬁcantly greater
than controls (8.3  1.0 mm; p < 0.001). Furthermore, HCM patients
showed worse wall thickening at LV maximal wall (24.2  16.8% vs.
77.5  23.5%, p < 0.001). There were no signiﬁcant differences in LV
chamber volumes and function (all p > 0.05). NYHA classes by clinical
symptoms were class I in eight patients, class II in four patients, class
III in four patients, and class IV in two patients.
Fibrotic size
Hyper-T1rho value was identiﬁed in 12 HCM patients,
consistent with LGE. The mean T1rho values of controls, LGE-
negative patients, and remote myocardium of LGE-positive
patients were 42.2  1.6 ms, 43.9  2.5 ms, and 42.5  1.2 ms
respectively, and these values showed no signiﬁcant differences
(all p > 0.05). Fig. 2 shows the location of hyper-T1rho value was in
concordance with LGE, and no hyper-T1rho value was observed in the
LGE-negative patient and control. With visual measurement, the
mean ﬁbrotic size calculated by LGE imaging was 28.1  11.2%atient, LGE-negative patient, and control. There was spatial correspondence between
ho relaxation times (B2, C2) were found in the LGE-negative patient and control (B1,
laxation time maps of the patients and control.
Fig. 3. Comparisons, correlations, and Bland–Altman plots of ﬁbrotic sizes determined by T1rho (3-SD and 4-SD) and late gadolinium enhancement (LGE). The upper three
panels show the nonsigniﬁcant difference (left), signiﬁcant correlation (middle), and minor mean difference between T1rho (3-SD) and LGE ﬁbrotic sizes. The lower three
panels show the nonsigniﬁcant difference (left), signiﬁcant correlation (middle), and minor mean difference between T1rho (4-SD) and LGE ﬁbrotic sizes.
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assessed by T1rho imaging were 41.2  17.4% at 2 SDs, 32.5  14.0%
at 3 SDs, 25.1  11.5% at 4 SDs, 19.3  9.6% at 5 SDs, and 15.2  8.3% at
6 SDs. Fibrotic sizes determined by T1rho-3-SD and T1rho-4-SD
methods showed no differences from that calculated by LGE (T1rho-3-
SD vs. LGE: p = 0.41; T1rho-4-SD vs. LGE: p = 0.52; Fig. 3). However,
ﬁbrotic size obtained by LGE imaging differed from those computed by
T1rho imaging at 2 SDs (p = 0.04), 5 SDs (p = 0.05), and 6 SDs (p = 0.004).
All ﬁbrotic sizes determined using T1rho method correlated signiﬁ-
cantly with that determined by LGE. However, the T1rho-3-SD method
obtained the strongest correlation (r = 0.88, p < 0.001; Fig. 3), com-
pared with the T1rho-2-SD (r = 0.84, p = 0.001), T1rho-4-SD (r = 0.85,
p < 0.001; Fig. 3), T1rho-5-SD (r = 0.847, p = 0.001), and T1rho-6-SD
(r = 0.81, p = 0.002). Bland–Altman analysis revealed that T1rho-4-SD
method obtained the minimal mean difference with LGE (3.1%; 15.2
to 9.1%; Fig. 3), compared with T1rho-2-SD (13.1%; 6.9 to 33%), T1rho-
3-SD (4.3%; 8.8 to 17.4%; Fig. 3), T1rho-5-SD (8.8%; 20.5 to 2.9%),
and T1rho-6-SD (12.9%; 26 to 0.1%).Table 2
Relationships between ﬁbrotic sizes (T1rho and LGE methods) and LV other parameter
T1rho-2-SD T1rho-3-SD 
LV mass 0.38, 0.28 0.36, 0.31 
LV maximal EDTH 0.75, 0.02 0.8, 0.01 
Wall thickening of LV maximal EDTH 0.44, 0.24 0.49, 0.18 
LVSV 0.21, 0.52 0.25, 0.44 
LVEF 0.42, 0.18 0.38, 0.22 
NYHA class 0.26, 0.42 0.28, 0.38 
Data are presented as r, p. LGE, late gadolinium enhancement; LV, left ventricular; NYHA
volume; LVEF, LV ejection fraction.Fibrotic size, wall thickness, and cardiac function
Correlations between ﬁbrotic sizes and LV other parameters
and NYHA class are summarized in Table 2. The ﬁbrotic sizes
computed by LGE and T1rho methods (all the ﬁve SDs) correlated
positively with LV maximal EDTH (LGE: r = 0.8, p = 0.01; T1rho-2-
SD: r = 0.75, p = 0.02; T1rho-3-SD: r = 0.8, p = 0.01; T1rho-4-SD:
r = 0.89, 0.001; T1rho-5-SD: r =0.91, p = 0.001; T1rho-6-SD:
r = 0.88, p = 0.002; Table 2 and Fig. 4). Nevertheless, no signiﬁcant
correlations were observed between ﬁbrotic sizes and LV mass,
wall thickening of LV maximal EDTH, LV chamber volumes, LV
stroke volume (LVSV), LV ejection fraction (LVEF), or NYHA class,
except for the inverse correlation between T1rho-6-SD ﬁbrotic size
and NYHA class (p < 0.05). However, for T1rho-4-SD ﬁbrotic size,
which is not signiﬁcantly different from LGE ﬁbrotic size, there
were high r and low p values in LVSV (r = 0.43, p = 0.16), LVEF
(r = 0.49, p = 0.11), NYHA class (r = 0.46, p = 0.13), and wall
thickening of LV maximal EDTH (r = 0.52, p = 0.15).s and NYHA class.
T1rho-4-SD T1rho-5-SD T1rho-6-SD LGE
0.32, 0.36 0.29, 0.42 0.23, 0.52 0.12, 0.75
0.89, 0.001 0.91, 0.001 0.88, 0.002 0.8, 0.01
0.52, 0.15 0.55, 0.13 0.53, 0.15 0.61, 0.08
0.43, 0.16 0.48, 0.11 0.55, 0.07 0.16, 0.63
0.49, 0.11 0.48, 0.12 0.51, 0.09 0.06, 0.86
0.46, 0.13 0.53, 0.08 0.61, 0.04 0.30, 0.34
, New York Heart Association; EDTH, end-diastolic wall thickness; LVSV, LV stroke
Fig. 4. Correlations between left ventricular (LV) maximal end-diastolic wall thickness (EDTH) and ﬁbrotic sizes with late gadolinium enhancement (LGE), T1rho-3-SD, and
T1rho-4-SD methods. Left panel shows LV maximal EDTH related positively to LGE ﬁbrotic size. Middle panel shows the positive correlation between LV maximal EDTH and
T1rho-3-SD ﬁbrotic size. Right panel shows LV maximal EDTH was directly associated with T1rho-3-SD ﬁbrotic size.
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HCM is an idiopathic disease with pathological myocardial
ﬁbrosis, which is considered to be associated with ventricular
arrhythmias and dysfunction [2,5,21]. To detect myocardial
ﬁbrosis, LGE was clinically validated and widely studied in HCM
[22]. However, LGE is not able to be applied in patients with
contrast agent contraindications. To the best of our knowledge,
endogenous contrast T1rho method has not previously been used
in assessment of ﬁbrosis in HCM patients.
Our preliminary data showed that ﬁbrotic sizes determined by
T1rho CMR at 3-SD and 4-SD did not signiﬁcantly differ from and
associated strongly with that determined by LGE CMR. Addition-
ally, 3-SD and 4-SD T1rho methods showed minor mean
differences with LGE. Witschey et al. [13] reported an agreement
in infarct sizes between T1rho and LGE methods in a porcine model
of chronic MI. The mechanism of LGE involves the difference of
contrast agent washout between remote myocardium and ﬁbrosis
[23]. LGE in HCM is likely to occur in replacement ﬁbrosis including
increased collagen concentration [7,24,25]. T1rho endogenous
contrast involves different water proton interactions, including
chemical exchange, dipole–dipole coupling, and diffusion
[13]. Moreover, elevated T1rho relaxation time is most likely to
imply granulation and scar tissue in myocardial infarction model
[18]. Taken together, T1rho and LGE can detect replacement
ﬁbrosis in chronic phase, suggesting the right threshold for ﬁbrotic
size calculated by T1rho may be the SD which is in strongest
accordance with LGE. Thus, hyper-T1rho value can be deﬁned as
the value greater than this SD above mean value of remote
myocardium. Given the overestimated infarct size by LGE and
T1rho compared with histology [13], in present study, 4-SD may be
the appropriate threshold.
The current study showed ﬁbrotic sizes calculated by both LGE
and T1rho methods were associated with LV maximal EDTH,
conﬁrming previous investigation that scarring extent correlated
with EDTH [1]. Myocardial ﬁbrosis is possibly considered as a long-
term result of microvascular ischemia, ultimately leading to
systolic abnormality in HCM, conﬁrmed by the inverse correlation
between ﬁbrotic extent and LVEF [11,26–28]. However, our study
found negative correlation (but not signiﬁcant) between LVEF and
T1rho-4-SD ﬁbrotic size. In clinical respect, the presence of
myocardial ﬁbrosis in HCM is modestly associated with heart
failure symptoms, and correlation between myocardial ﬁbrosis
and NYHA class has been found [12,27], suggesting ﬁbrotic size
may be a predictor of NYHA class. However, our results showed a
negative correlation with nonsigniﬁcance between T1rho-4-SD
ﬁbrotic size and NYHA class. Moreover, there is a study whichincluded a relatively small population, showing no correlation
between ﬁbrotic extent and LVEF or NYHA class [2]. Thus,
nonsigniﬁcant correlation between ﬁbrotic size and LV function
and NYHA class may be contributed by small sample or different
spectrum of HCM patients.
Longitudinal rotating-frame relaxation time T1rho is contrib-
uted by magnetic ﬁeld ﬂuctuation because of on-off binding water
molecules [29]. T1rho tissue properties become similar to T2 tissue
contrast as B1 is at a certain value [30], which may be explained by
the interactions of water protons. The interactions of macromo-
lecular water include dipole–dipole coupling, chemical exchange,
and diffusion. However, the dominant T1rho relaxation mecha-
nism is still unknown [13,31]. Myocardial scar was found to cause
T1rho relaxation alteration compared with healthy myocardium
[31]. Musthafa et al. [18] found T1rho relaxation times were
elevated nonsigniﬁcantly at day 3 and further increased signiﬁ-
cantly at days 7 and 14, indicating the hyper-T1rho value possibly
represents the ﬁbrosis in chronic phase, corresponding to the study
of Witschey et al. [31]. However, T1rho value increased immedi-
ately after cerebral infarction in rat models [32]. Additionally,
T1rho correlated directly to proteoglycan content in intervertebral
discs, whereas it was related inversely to that in articular cartilage,
suggesting that the relative composition in different tissue affects
T1rho [33]. The above studies indicate T1rho alteration, including
value and time course, may differ in different tissue due to various
composition or relative composition. Nevertheless, abnormal
T1rho relaxation time was associated with granulation or scar
tissue by histology in swine and rat MI models [13,18], suggesting
T1rho methods may augment or even replace LGE CMR.
Van Oorschot et al. [34] reviewed several types of CMR
techniques. Compared with LGE, T1rho CMR without contrast
agent may assess the ﬁbrotic size and is free of anaphylactic
reactions and nephrogenic systemic ﬁbrosis (NSF). Extracellular
volume (ECV) mapping is excellent for diffuse ﬁbrosis. But ECV
method needs dozens of minutes for contrast equilibrium and
involves acquirement of pre- and post-contrast maps as well as
hematocrit value [35,36]. T1rho method is simple and time-saving,
with no need for gadolinium agent, acquisition of two different-
time maps, or patients’ blood in comparison with ECV mapping.
Native T1 mapping for diffuse ﬁbrosis is also independent of renal
function due to no need for contrast agent. However, change is very
small between ﬁbrosis and remote myocardium [37]. T1rho
relaxation times have a wider range of values compared with T1
relaxation, and seem to associate earlier and better with
therapeutic response and disease progression [38].
There were several limitations to this study. Firstly, the sample
size was relatively small, but our data have highlighted a
C. Wang et al. / Journal of Cardiology 66 (2015) 520–526 525promising method for patients with contrast agent contraindica-
tions. Secondly, there were no pathologic data to support one SD
threshold for ﬁbrotic size. However, we analyzed the agreement
between T1rho threshold and LGE visual methods for ﬁbrotic sizes
despite the different contrast mechanisms. Finally, 340 Hz was the
largest spin-locking frequency we could use with the limitation of
SAR imposed by the MRI system and limited breath-holding time
despite 500 Hz being commonly selected [13,17]. It is necessary for
a further larger cohort study with modiﬁed T1rho technique.
In conclusion, ﬁbrotic size assessed by T1rho CMR at 4-SD was
in good agreement with LGE, and associated with LV maximal
EDTH. 4-SD may be the right threshold for ﬁbrotic assessment
using T1rho method. Overall, the non-contrast T1rho CMR is
promising to detect ﬁbrosis in HCM patients and provides an
option for HCM patients with contrast agent contraindications.
Funding
This work was supported by the National Natural Science
Foundation of China [grant number 81130027] [http://www.nsfc.
gov.cn/Portal0/default166.htm], and the National Basic Research
Program of China [973 Program, grant number 2011CB935800]
[http://www.973.gov.cn/English/Index.aspx], and Key Projects in
the National Science & Technology Pillar Program during the
Twelfth Five-year Plan Period [grant number 2012BAI23B08].
Conﬂict of interest
The authors declare that there is no conﬂict of interest.
References
[1] Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, Bonow
RO, Judd RM, Kim RJ. Myocardial scarring in asymptomatic or mildly symp-
tomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;
40:2156–64.
[2] Choi DS, Ha JW, Choi B, Yang WI, Choi EY, Rim SJ, Chung N. Extent of late
gadolinium enhancement in cardiovascular magnetic resonance and its rela-
tion with left ventricular diastolic function in patients with hypertrophic
cardiomyopathy. Circ J 2008;72:1449–53.
[3] Motoyasu M, Kurita T, Onishi K, Uemura S, Tanigawa T, Okinaka T, Takeda K,
Nakano T, Ito M, Sakuma H. Correlation between late gadolinium enhance-
ment and diastolic function in hypertrophic cardiomyopathy assessed by
magnetic resonance imaging. Circ J 2008;72:378–83.
[4] Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K,
Schlosser T, Sabin GV, Sechtem U, Mahrholdt H. Myocardial scar visualized by
cardiovascular magnetic resonance imaging predicts major adverse events in
patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:
875–87.
[5] Varnava AM, Elliott PM, Mahon N, Davies MJ, McKenna WJ. Relation between
myocyte disarray and outcome in hypertrophic cardiomyopathy. Am J Cardiol
2001;88:275–9.
[6] Lamke GT, Allen RD, Edwards WD, Tazelaar HD, Danielson GK. Surgical
pathology of subaortic septal myectomy associated with hypertrophic cardio-
myopathy. A study of 204 cases (1996–2000). Cardiovasc Pathol 2003;12:
149–58.
[7] Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, Petrou M,
Pennell DJ. The histologic basis of late gadolinium enhancement cardiovascu-
lar magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol
2004;43:2260–4.
[8] Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;
287:1308–20.
[9] Maron BJ, Pelliccia A. The heart of trained athletes: cardiac remodeling and the
risks of sports, including sudden death. Circulation 2006;114:1633–44.
[10] Fujita T, Konno T, Yokawa J, Masuta E, Nagata Y, Fujino N, Funada A, Hodatsu A,
Kawashiri MA, Yamagishi M, Hayashi K. Increased extent of myocardial
ﬁbrosis in genotyped hypertrophic cardiomyopathy with ventricular tachyar-
rhythmias. J Cardiol 2014. pii:S0914-5087(14)00294-9.
[11] Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, Bos
JM, Tajik AJ, Valeti US, Nishimura RA, Gersh BJ. Characteristics and clinical
signiﬁcance of late gadolinium enhancement by contrast-enhanced magnetic
resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart
Fail 2010;3:51–8.
[12] Aquaro GD, Masci P, Formisano F, Barison A, Strata E, Pingitore A, Positano V,
Spirito P, Lombardi M. Usefulness of delayed enhancement by magneticresonance imaging in hypertrophic cardiomyopathy as a marker of disease
and its severity. Am J Cardiol 2010;105:392–7.
[13] Witschey WR, Zsido GA, Koomalsingh K, Kondo N, Minakawa M, Shuto T,
McGarvey JR, Levack MM, Contijoch F, Pilla JJ, Gorman 3rd JH, Gorman RC. In
vivo chronic myocardial infarction characterization by spin locked cardiovas-
cular magnetic resonance. J Cardiovasc Magn Reson 2012;14:37.
[14] Wang L, Chang G, Bencardino J, Babb JS, Krasnokutsky S, Abramson S, Regatte
RR. T1rho MRI of menisci in patients with osteoarthritis at 3 Tesla: a prelimi-
nary study. J Magn Reson Imaging 2013;40:588–95.
[15] Zhou Z, Jiang B, Zhou Z, Pan X, Sun H, Huang B, Liang T, Ringgaard S, Zou X.
Intervertebral disk degeneration: T1rho MR imaging of human and animal
models. Radiology 2013;268:492–500.
[16] Haris M, Singh A, Cai K, Davatzikos C, Trojanowski JQ, Melhem ER, Clark CM,
Borthakur A. T1rho (t1rho) MR imaging in Alzheimer’s disease and Parkinson’s
disease with and without dementia. J Neurol 2011;258:380–5.
[17] Zhao F, Wang YX, Yuan J, Deng M, Wong HL, Chu ES, Go MY, Teng GJ, Ahuja AT,
Yu J. MR t1rho as an imaging biomarker for monitoring liver injury progression
and regression: an experimental study in rats with carbon tetrachloride
intoxication. Eur Radiol 2012;22:1709–16.
[18] Musthafa HS, Dragneva G, Lottonen L, Merentie M, Petrov L, Heikura T, Yla-
Herttuala E, Yla-Herttuala S, Grohn O, Liimatainen T. Longitudinal rotating
frame relaxation time measurements in infarcted mouse myocardium in vivo.
Magn Reson Med 2013;69:1389–95.
[19] Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O’Connell J, Olsen
E, Thiene G, Goodwin J, Gyarfas I, Martin I, Nordet P. Report of the 1995 World
Health Organization/International Society and Federation of Cardiology Task
Force on the Deﬁnition and Classiﬁcation of cardiomyopathies. Circulation
1996;93:841–2.
[20] McCommis KS, He X, Abendschein DR, Gupte PM, Gropler RJ, Zheng J. Cardiac
17O MRI: toward direct quantiﬁcation of myocardial oxygen consumption.
Magn Reson Med 2010;63:1442–7.
[21] Todiere G, Aquaro GD, Piaggi P, Formisano F, Barison A, Masci PG, Strata E,
Bacigalupo L, Marzilli M, Pingitore A, Lombardi M. Progression of myocardial
ﬁbrosis assessed with cardiac magnetic resonance in hypertrophic cardiomy-
opathy. J Am Coll Cardiol 2012;60:922–9.
[22] Stirrat J, White JA. The prognostic role of late gadolinium enhancement
magnetic resonance imaging in patients with cardiomyopathy. Can J Cardiol
2013;29:329–36.
[23] Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward
clinical risk assessment in hypertrophic cardiomyopathy with gadolinium
cardiovascular magnetic resonance. J Am Coll Cardiol 2003;41:1561–7.
[24] Kim RJ, Judd RM. Gadolinium-enhanced magnetic resonance imaging in
hypertrophic cardiomyopathy: in vivo imaging of the pathologic substrate
for premature cardiac death? J Am Coll Cardiol 2003;41:1568–72.
[25] O’Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni
M, Dawson D, Sulaibeekh L, Chandrasekaran B, Bucciarelli-Ducci C, Pasquale F,
Cowie MR, McKenna WJ, et al. Prognostic signiﬁcance of myocardial ﬁbrosis in
hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:867–74.
[26] Matoh F, Satoh H, Shiraki K, Saitoh T, Urushida T, Katoh H, Takehara Y,
Sakahara H, Hayashi H. Usefulness of delayed enhancement magnetic reso-
nance imaging to differentiate dilated phase of hypertrophic cardiomyopathy
and dilated cardiomyopathy. J Card Fail 2007;13:372–9.
[27] Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR,
Udelson JE, Manning WJ, Maron BJ. Clinical proﬁle and signiﬁcance of delayed
enhancement in hypertrophic cardiomyopathy. Circ Heart Fail 2008;1:
184–91.
[28] Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, Udelson
JE, O’Donnell C, Lesser JR, Manning WJ, Maron MS. Spectrum and clinical
signiﬁcance of systolic function and myocardial ﬁbrosis assessed by cardio-
vascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol
2010;106:261–7.
[29] Brown 3rd RD, Koenig SH. 1/t1 rho and low-ﬁeld 1/t1 of tissue water protons
arise from magnetization transfer to macromolecular solid-state broadened
lines. Magn Reson Med 1992;28:145–52.
[30] Huber S, Muthupillai R, Lambert B, Pereyra M, Napoli A, Flamm SD. Tissue
characterization of myocardial infarction using t1rho: inﬂuence of contrast
dose and time of imaging after contrast administration. J Magn Reson Imaging
2006;24:1040–6.
[31] Witschey WR, Pilla JJ, Ferrari G, Koomalsingh K, Haris M, Hinmon R, Zsido G,
Gorman 3rd JH, Gorman RC, Reddy R. Rotating frame spin lattice relaxation in
a swine model of chronic, left ventricular myocardial infarction. Magn Reson
Med 2010;64:1453–60.
[32] Kettunen MI, Grohn OH, Penttonen M, Kauppinen RA. Cerebral t1rho relaxa-
tion time increases immediately upon global ischemia in the rat independent-
ly of blood glucose and anoxic depolarization. Magn Reson Med 2001;46:
565–72.
[33] Johannessen W, Auerbach JD, Wheaton AJ, Kurji A, Borthakur A, Reddy R, Elliott
DM. Assessment of human disc degeneration and proteoglycan content using
t1rho-weighted magnetic resonance imaging. Spine (Phila Pa 1976)
2006;31:1253–7.
[34] van Oorschot JW, Gho JM, van Hout GP, Froeling M, Jansen Of Lorkeers SJ,
Hoefer IE, Doevendans PA, Luijten PR, Chamuleau SA, Zwanenburg JJ. Endoge-
nous contrast MRI of cardiac ﬁbrosis: beyond late gadolinium enhancement.
J Magn Reson Imaging 2014. http://dx.doi.org/10.1002/jmri.24715.
[35] Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM,
McGregor C, Moon JC. Equilibrium contrast cardiovascular magnetic resonance
C. Wang et al. / Journal of Cardiology 66 (2015) 520–526526for the measurement of diffuse myocardial ﬁbrosis: preliminary validation in
humans. Circulation 2010;122:138–44.
[36] Wong TC. Cardiovascular magnetic resonance imaging of myocardial intersti-
tial expansion in hypertrophic cardiomyopathy. Curr Cardiovasc Imaging Rep
2014;7:9267.
[37] Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M, Francis JM,
Karamitsos TD, Prendergast BD, Robson MD, Neubauer S, Moon JC, MyersonSG. Human non-contrast t1 values and correlation with histology in diffuse
ﬁbrosis. Heart 2013;99:932–7.
[38] Andronesi OC, Bhat H, Reuter M, Mukherjee S, Caravan P, Rosen BR. Whole
brain mapping of water pools and molecular dynamics with rotating frame MR
relaxation using gradient modulated low-power adiabatic pulses. Neuroimage
2014;89:92–109.
